FGF23 levels increase during heart failure exacerbations, correlate with disease severity, and predict the risk of heart failure-related death and hospitalization, as well as the likelihood of a therapeutic response to angiotensin-converting enzyme inhibitor (ACE inhibitor) medication, regardless of kidney function [10]. Here, ACE is linked to heart failure.